45 results on '"Hay, Justin L."'
Search Results
2. A review of clinical pharmacology deficiencies of European centralised drug marketing authorisation applications
3. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
4. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans
5. Pediatric oncology drug development and dosage optimization.
6. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine
7. Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models
8. Responsiveness of electrical nociceptive detection thresholds to capsaicin (8 %)-induced changes in nociceptive processing
9. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans
10. Model of methadone-induced hyperalgesia in rats and effect of memantine
11. Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019
12. The effects of the nonselective benzodiazepine lorazepam and the α2/α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels
13. Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients
14. Antinociceptive effects of high dose remifentanil in male methadone-maintained patients
15. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers
16. Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Na v 1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects
17. Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs
18. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia
19. Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models
20. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects
21. Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects.
22. Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models
23. Model‐based exposure‐response analysis to quantify age related differences in the response to scopolamine in healthy subjects
24. European regulatory perspective on pediatric physiologically based pharmacokinetic models
25. The use of a battery of pain models to detect analgesic properties of compounds: a two‐part four‐way crossover study
26. Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties
27. A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models
28. Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica
29. Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
30. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers
31. Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties.
32. Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects.
33. A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.
34. The effects of the nonselective benzodiazepine lorazepam and the α2/α3subunit-selective GABAAreceptor modulators AZD7325 and AZD6280 on plasma prolactin levels
35. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3receptor antagonist GSK1144814 in alcohol-intoxicated volunteers
36. The effects of the nonselective benzodiazepine lorazepam and the α2/α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.
37. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
38. Commentary on the MID3 Good Practices Paper.
39. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.
40. Model of methadone-induced hyperalgesia in rats and effect of memantine
41. Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients
42. Lack of Detection of the Analgesic Properties of PF-05089771, a Selective Na v 1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects.
43. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.
44. The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.
45. Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.